![]() |
市场调查报告书
商品编码
1368689
单细胞组学市场- 按产品类型(基因组学、转录组学、蛋白质组学、代谢组学)、应用(肿瘤学、细胞生物学、神经学、免疫学)、最终用户(製药和生物技术公司、医院实验室)、全球预测(2023 - 2032 年) )Single-cell Omics Market - By Product Type (Genomics, Transcriptomics, Proteomics, Metabolomics), Application (Oncology, Cell Biology, Neurology, Immunology), End-user (Pharma & Biotech Companies, Hospital Laboratories), Global Forecast (2023 - 2032) |
由于个人化治疗的需求不断增长,单细胞组学市场规模预计从 2023 年到 2032 年复合年增长率将超过 20%。随着癌症和自体免疫疾病等复杂疾病的盛行率不断上升,需要量身定制的治疗方法。根据一项针对 2,200 万人的最新研究,在英国,近 10% 的人口患有 19 种自体免疫疾病。
此外,生物技术和基因组学研究的快速进步,加上对理解细胞异质性的关注,正在推动单细胞组学技术在各种研究和临床应用中的采用。
整个单细胞组学市场根据产品类型、应用、最终用户和地区进行分类。
由于强调揭示单一细胞内复杂的蛋白质动态,单细胞蛋白质体学领域预计 2023 年至 2032 年的复合年增长率将达到 20.6%。蛋白质体学可以深入了解细胞功能和蛋白质相互作用。新兴技术正在彻底改变研究人员和临床医生在单细胞层级研究蛋白质表现和翻译后修饰的方式,从而促进疾病研究和药物开发的突破性见解。
随着单细胞组学在许多研究领域展现其变革潜力,细胞生物学领域在 2023 年至 2032 年期间的复合年增长率将达到 20.5%。从破解肿瘤异质性的复杂性到揭示免疫细胞多样性的复杂性,单细胞组学技术正在使细胞生物学研究取得前所未有的进展。透过提供对细胞行为的细緻入微的理解,这些技术正在增强新治疗标靶的识别并促进精确治疗策略的发展,从而促进再生医学、免疫疗法和发育生物学领域的突破。
由于该地区生物技术研究的大幅增长,预计亚太地区单细胞组学产业规模从 2023 年到 2032 年的复合年增长率将达到 20.7%。中国、日本和韩国等国家越来越关注精准医疗计画。研发投资的快速成长,加上慢性病盛行率的上升,推动了不同临床和研究环境对先进单细胞组学解决方案的需求,凸显了该地区在塑造精准医疗未来方面的关键作用。
The single-cell omics market size to expected record over 20% CAGR from 2023 to 2032, owing to the escalating demand for personalized therapeutics. With the rising prevalence of complex diseases such as cancer and autoimmune disorders, there is a need for tailored treatments. According to a latest study based on 22 million people, in UK, nearly 10% of the population is suffering from a list of 19 autoimmune disorders.
Furthermore, the rapid advancements in biotechnology and genomics research, coupled with the focus on understanding cellular heterogeneity, are driving the adoption of single cell omics technologies across diverse research and clinical applications.
The overall single-cell omics market is classified as per product type, application, end-user, and region.
The single-cell proteomics segment is anticipated to record 20.6% CAGR from 2023 to 2032 owing to the emphasis on unraveling intricate protein dynamics within individual cells. The proteomics enable in-depth understanding of cellular functions and protein interactions. Emerging technologies are revolutionizing the way researchers and clinicians approach the study of protein expression and post-translational modifications at the single-cell level, thereby facilitating groundbreaking insights for disease research and drug development.
The cell biology segment will observe 20.5% CAGR during 2023-2032 as single cell omics is demonstrating its transformative potential across a myriad of research domains. From deciphering the complexities of tumor heterogeneity to unraveling the intricacies of immune cell diversity, single cell omics technologies are enabling unprecedented advancements in cell biology research. By providing a nuanced understanding of cellular behavior, these technologies are enhancing the identification of novel therapeutic targets and fostering the development of precise treatment strategies, thus fostering breakthroughs in the fields of regenerative medicine, immunotherapy, and developmental biology.
Asia Pacific single cell omics industry size is predicted to witness 20.7% CAGR from 2023 to 2032 owing to the significant upsurge in biotechnology research across the region. There is mounting focus on precision medicine initiatives in countries such as China, Japan, and South Korea. The burgeoning investments in R&D, coupled with the rising prevalence of chronic diseases, are propelling the demand for advanced single cell omics solutions across diverse clinical and research settings, thereby underscoring the region's pivotal role in shaping the future of precision medicine.